According to a Reuters report and a media release this morning, Medivation has announced that interim results of the Phase III AFFIRM trial showed a 4.8-month survival benefit for treatment with MDV3100 compared to a placebo in men with metastatic, castration-resistant prostate cancer after treatment with docetaxel-based chemotherapy.
According to the media release, an independent monitoring committee has recommended stopping this trial of MDV3100, arguing that the investigational drug showed enough benefit to warrant giving it to patients who were originally randomized to the placebo.
The estimated median survival for men treated with MDV3100 was 18.4 months, while those treated with placebo had a survival of 13.6 months. No information is yet available on side effects observed in this clinical trial.
Filed under: Drugs in development, Management, Treatment | Tagged: AFFIRM, mCRPC, MDV3100, outcome |
THE "NEW" PROSTATE CANCER INFOLINK 
This is the very bestest news. This drug may also have an effect on breast cancer.
Many heartfelt thanks to Charles Sawyers and David Jung who developed this drug and who are working still on “son of MDV”: ARN509.
To Drs. Sawyers and Jung. THANK YOU! (Yes, I am shouting!)
I also SHOUT with you JC, This is indeed good news! THANKS DR. SAWYERS!!!